ABSTRACT
Objective:To explore the prevention and control strategies and effects of COVID-19 in People's Hospital of Tongchuan so as to provide evidence for prevention and control of COVID-19 in Tongchuan.Methods:Themeasures taken by People's Hospital of Tongchuan from the aspects of sound organization, new coronavirus knowledge training, prevention of nosocomial infection, establishment of elite medical team, scientific and precise treatment and internet applicationas well as medical treatment were reviewed. Results:Between 23 January 2020 and 15 April 2020, the hospital had received a total of 6 patients with confirmed COVID-19, among which 3 patients have been discharged. More than 31,000 persons were given pre-examination triage, 2,605 persons were treated for fever at clinics, 596 persons were under isolation and observation, and 184 persons had nucleic acid test, so as to achieve the requirements of no missed diagnosis, no death and no infection goal, which were prioritized by the national, provincial and municipal health inspection teams.Conclusion:The effective prevention and control strategies against COVID-19 in People’s Hospital of Tongchuan have significantly achieved the "three zeros" goal namely zero infection, zero transmission and zero death.People's Hospital of Tongchuan, founded in 1949, is a comprehensive level-III first-class hospital. It has two hospitals located in the north and the south, with 1,700 beds and 2,044 employees. It is the first designated hospital for treatment of COVID-19 [1]in the province.
ABSTRACT
The tuberous sclerosis complex (TSC) in children is also named Bourneville disease,the 3 main symptoms namely epilepsy,mental retardation and facial angiofibromas.It is an autosomal dominant disease.It is an important cause of epilepsy,skin disease,and renal and pulmonary disease in children and adults.The appropriate therapy and prognosis for TSC patients are often different than that for individuals with epilepsy,renal tumors,or interstitial lung disease from other causes.In recent years,certain progress has been made in management of tuberous sclerosis,inhibitors of the mammalian target of rapamycin (mTOR) have demonstrated regression of astrocytomas,angiofibromas,and angiomyoliomas,as well as improved pulmonary function in persons with TSC.This article reviews the current therapeutic recommendations for medical and surgical management of neurologic,renal,and pulmonary manifestations of TSC.
ABSTRACT
Chuanxiong is a herb used in traditional Chinese medicine for the Treatment of viral encephalitis. In animal studies it has shown to inhibit the synthesis and activity of Thromboxane [TXA2] and abate the imbalance between Thromboxane [TXA2] and Prostacyclin [PGI2]. As a result, cerebral edema, ischemia and hypoxia could be improved. The aim of this study is to evaluate its effect in the treatment of viral encephalitis in children
Methodology: ninety-nine patients with viral encephalitis were randomly divided into two groups. Ligustrazini Hydrochlorioi [LH] consisting of 51 cases [males 30, females 21; age 5 years and nine month +/- 8 years and 2month] was given LH 4mg/kg per day in 100- 300mls of 10% glucose and infused intravenously over a three to four hour period, for 7 days as a course of treatment. A control groups of 48 cases [males 31, females 17; age 5 years and three month +/- 4 years and three month] received the conventional treatment of Vitamin C[2.0-3.0g], Coenzyme A[100u] and Adenosine Triphosphate [ATP] [40mg] in 100-300 mls of 10% glucose infused intravenously daily for 7 days
Results: the total response rate in the LH group and the control group were 94.12% and 68.75% respectively [u=3.271 p<0.05]. The average time to improvement was 4.29 +/- 1.41 days and 7.31 +/- 2.66 days respectively. No adverse effect was observed in both groups
Conclusion: we conclude that LH is an effective, safe and well tolerated treatment for children encephalitis